The Value of Nutritional Status in the Prognostic Analysis of Patients with AIDS-Related Lymphoma

References

• Qiao YC, Xu Y, Jiang DX, et al. Epidemiological analyses of regional and age differences of HIV/AIDS prevalence in China, 2004–2016. Int J Infect Dis. 2019;81:215–220. doi:10.1016/j.ijid.2019.02.01630797071
   PubMed Web of Science ®Google Scholar
• Bruyand M, Thiébaut R, Lawson-Ayayi S, et al.; Groupe d’Epidémiologie Clinique du SIDA en Aquitaine (GECSA). Role of uncontrolled HIV RNA level and immunodeficiency in the occurrence of malignancy in HIV-infected patients during the combination antiretroviral therapy era: Agence Nationale de Recherche sur le Sida (ANRS) CO3 aquitaine cohort. Clin Infect Dis. 2009;49(7):1109–1116. doi:10.1086/60559419705973
   PubMed Web of Science ®Google Scholar
• Kang R, Li J, Chen H, et al. Using longitudinal genetic-network study to understand HIV treatment-as-prevention: a population-based observational study. AIDS. 2021. doi:10.1097/QAD.0000000000002812
   Web of Science ®Google Scholar
• Pather S, Mashele T, Willem P, et al. MYC status in HIV-associated Plasmablastic lymphoma: dual-colour CISH, FISH and immunohistochemistry. Histopathology. 2021. doi:10.1111/his.14336
   Web of Science ®Google Scholar
• Franceschi S, Lise M, Clifford GM, et al; Swiss HIV Cohort Study. Changing patterns of cancer incidence in the early- and late-HAART periods: the Swiss HIV Cohort Study. Br J Cancer. 2010;103(3):416–422. doi:10.1038/sj.bjc.660575620588274
   PubMed Web of Science ®Google Scholar
• Siddiqui RS, Agladze M, Bashir T. Hemophagocytic lymphohistiocytosis as the presenting manifestation of relapsed classic hodgkin’s lymphoma in the presence of concurrent human immunodeficiency virus, genital herpes, epstein-barr virus and mycobacterium avium complex infection. Cureus. 2020;12(11):e11563.33364090
   PubMed Web of Science ®Google Scholar
• Bohlius J, Schmidlin K, Costagliola D, et al.; Collaboration of Observational HIV Epidemiological Research Europe (COHERE) study group. Prognosis of HIV-associated non-hodgkin lymphoma in patients starting combination antiretroviral therapy. AIDS. 2009;23(15):2029–2037. doi:10.1097/QAD.0b013e32832e531c19531926
   PubMed Web of Science ®Google Scholar
• McMillan DC. Systemic inflammation, nutritional status and survival in patients with cancer. Curr Opin Clin Nutr Metab Care. 2009;12(3):223–226. doi:10.1097/MCO.0b013e32832a790219318937
   PubMed Web of Science ®Google Scholar
• Li H, Q Y M, Tang SR, Shi LC. Effects of enteral nutrition support on antiviral therapy for AIDS patients. Nurs Res. 2013;27(18):1873–1874.
   Google Scholar
• Mori N, Wildes F, Takagi T, Glunde K, Bhujwalla ZM. The tumor microenvironment modulates choline and lipid metabolism. Front Oncol. 2016;6:262. doi:10.3389/fonc.2016.0026228066718
   PubMed Web of Science ®Google Scholar
• Hashimoto N, Ueda T, Hiraiwa S, Tajiri T, Nakamura N, Yokoyama K. Clonally related plasmablastic lymphoma simultaneously occurring with diffuse large B-cell lymphoma. Case Rep Hematol. 2020;2020:8876567. doi:10.1155/2020/887656733335784
   PubMed Web of Science ®Google Scholar
• Zhou Q, Wei Y, Huang F, et al. Low prognostic nutritional index predicts poor outcome in diffuse large B-cell lymphoma treated with R-CHOP. Int J Hematol. 2016;104(4):485–490. doi:10.1007/s12185-016-2052-927393279
   PubMed Web of Science ®Google Scholar
• Hao X, Wei Y, Wei X, et al. Glasgow prognostic score is superior to other inflammation-based scores in predicting survival of diffuse large B-cell lymphoma. Oncotarget. 2017;8(44):76740–76748. doi:10.18632/oncotarget.2083229100345
   PubMedGoogle Scholar
• Miura K, Konishi J, Miyake T, et al. A host-dependent prognostic model for elderly patients with diffuse large B-cell lymphoma. Oncologist. 2017;22(5):554–560. doi:10.1634/theoncologist.2016-026028408622
   PubMed Web of Science ®Google Scholar
• Park S, Han B, Cho JW, et al. Effect of nutritional status on survival outcome of diffuse large B-cell lymphoma patients treated with rituximab-CHOP. Nutr Cancer. 2014;66(2):225–233. doi:10.1080/01635581.2014.86706524405259
   PubMed Web of Science ®Google Scholar
• Chinese Center for Disease Control and Prevention, AIDS and Hepatitis C Group, Chinese Association of Infectious Diseases. Chinese Medical Association Chinese guidelines for diagnosis and treatment of HIV/AIDS. Electron J Emerg Infect Dis. 2018;2018(6).
   Google Scholar
• Duan R. WHO classification of hematopoietic and lymphoid tumors. Chin J Diagn Pathol. 2016;2017(12):956–958.
   Google Scholar
• Cederholm T, Bosaeus I, Barazzoni R, et al. Diagnostic criteria for malnutrition - an ESPEN consensus statement. Clin Nutr. 2015;34(3):335–340. doi:10.1016/j.clnu.2015.03.00125799486
   PubMed Web of Science ®Google Scholar
• Rondel ALMA, Langius JAE, de van der Schueren MAE, Kruizenga HM. The new ESPEN diagnostic criteria for malnutrition predict overall survival in hospitalised patients. Clin Nutr. 2018;37(1):163–168. doi:10.1016/j.clnu.2016.11.01827939358
   PubMed Web of Science ®Google Scholar
• Birlutiu V, Birlutiu RM, Zaharie IS, Sandu M. Burkitt lymphoma associated with human immunodeficiency virus infection and pulmonary tuberculosis: a case report. Medicine. 2020;99(52):e23853. doi:10.1097/MD.000000000002385333350777
   PubMed Web of Science ®Google Scholar
• Devoto G, Gallo F, Marchello C, et al. Prealbumin serum concentrations as a useful tool in the assessment of malnutrition in hospitalized patients. Clin Chem. 2006;52(12):2281–2285. doi:10.1373/clinchem.2006.08036617068165
   PubMed Web of Science ®Google Scholar
• Ribera JM, Navarro JT. Human immunodeficiency virus-related non-hodgkin’s lymphoma. Haematologica. 2008;93(8):1129–1132. doi:10.3324/haematol.1351918669976
   PubMed Web of Science ®Google Scholar
• Glushko T, He L, McNamee W, Babu AS, Simpson SA. HIV lymphadenopathy: differential diagnosis and important imaging features. AJR Am J Roentgenol. 2020;1–8. doi:10.2214/AJR.19.22334
   Web of Science ®Google Scholar
• Gordon JN, Green SR, Goggin PM. Cancer cachexia. QJM. 2005;98(11):779–788. doi:10.1093/qjmed/hci12716214835
   PubMed Web of Science ®Google Scholar
• Ikeda H, Kobune M, Nagashima K, et al. Diffuse large B cell lymphoma with HIV infection presented with disseminated thromboembolism during antiretroviral therapy. Rinsho Ketsueki. 2020;61(11):1595–1599. doi:10.11406/rinketsu.61.159533298652
   PubMedGoogle Scholar
• Shipp MA. Prognostic factors in aggressive non-hodgkin’s lymphoma: who has “high-risk” disease? Blood. 1994;83(5):1165–1173. doi:10.1182/blood.V83.5.1165.11658118021
   PubMed Web of Science ®Google Scholar
• Pfreundschuh M, Kuhnt E, Trümper L, et al.; MabThera International Trial (MInT) Group. CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group. Lancet Oncol. 2011;12(11):1013–1022. doi:10.1016/S1470-2045(11)70235-221940214
   PubMed Web of Science ®Google Scholar
• Ziepert M, Hasenclever D, Kuhnt E, et al. Standard international prognostic index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era. J Clin Oncol. 2010;28(14):2373–2380. doi:10.1200/JCO.2009.26.249320385988
   PubMed Web of Science ®Google Scholar
• Shang H, Wang L. Experimental Diagnostics. 3rd ed. Beijing: People’s Medical Publishing House; 2015:172–177.
   Google Scholar
• Ingenbleek Y, Young VR. Significance of transthyretin in protein metabolism. Clin Chem Lab Med. 2002;40(12):1281–1291. doi:10.1515/CCLM.2002.22212553432
   PubMed Web of Science ®Google Scholar
• Ribera JM, Oriol A, Morgades M, et al; PETHEMA, GELTAMO, GELCAB and GESIDA Groups. Safety and efficacy of cyclophosphamide, adriamycin, vincristine, prednisone and rituximab in patients with human immunodeficiency virus-associated diffuse large B-cell lymphoma: results of a Phase II trial. Br J Haematol. 2008;140(4):411–419. doi:10.1111/j.1365-2141.2007.06943.x18162120
   PubMed Web of Science ®Google Scholar
• Schommers P, Gillor D, Hentrich M, et al. Incidence and risk factors for relapses in HIV-associated non-hodgkin lymphoma as observed in the German HIV-related lymphoma cohort study. Haematologica. 2018;103(5):857–864. doi:10.3324/haematol.2017.18089329439188
   PubMed Web of Science ®Google Scholar
• Kaplan LD. Management of HIV-associated hodgkin lymphoma: how far we have come. J Clin Oncol. 2012;30(33):4056–4058. doi:10.1200/JCO.2012.44.837323045587
   PubMed Web of Science ®Google Scholar